RESTATEMENT OF FINANCIAL STATEMENTS (Details) - USD ($)		3 Months Ended			6 Months Ended
		Jun. 30, 2018	Jun. 30, 2017		Jun. 30, 2018	Jun. 30, 2017
Revenue			$ 41,000			$ 83,000
Operating costs:
Direct cost of revenue		4,000	65,000		7,000	127,000
General and administrative expenses		373,000	310,000		768,000	1,024,000
Research and development		21,000	(669,000)		52,000	155,000
Total operating costs and expenses		398,000	(294,000)		827,000	1,306,000
Loss from operations before other income and expenses		(398,000)	335,000		(827,000)	(1,223,000)
Other income and (expenses):
(Loss) on fair value adjustment of investments		(973,000)	203,000		(3,373,000)	203,000
Gain on deconsolidation of subsidiary			7,940,000			7,940,000
Interest and other expenses			96,000
NET INCOME (LOSS) INCLUDING NONCONTROLLABLE INTEREST		(1,371,000)	8,574,000		(4,199,000)	6,920,000
Net (loss) attributable to noncontrolling interest			(472,000)
NET (LOSS) ATTRIBUTABLE TO MANHATTAN SCIENTIFICS, INC.		$ (1,371,000)	$ 9,046,000		$ (4,199,000)	$ 6,920,000
BASIC AND DILUTED INCOME (LOSS) PER COMMON SHARE:
Weighted average number of common shares outstanding (Basic)		533,781,064	533,781,064		533,781,064	533,781,064
Basic income (loss) per common share		$ (0.00)	$ 0.02		$ (0.01)	$ 0.01
Weighted average number of common shares outstanding (Diluted)		533,781,064	530,163,579		533,781,064	581,036,064
Diluted income (loss) per common share		$ (0.00)	$ 0.02		$ (0.01)	$ 0.01
(Original Amount)
Revenue			$ 41,000			$ 83,000
Operating costs:
Direct cost of revenue
General and administrative expenses			367,000			1,143,000
Research and development			(658,000)			166,000
Total operating costs and expenses			(291,000)			1,309,000
Loss from operations before other income and expenses			332,000			(1,226,000)
Other income and (expenses):
Gain from change in accounting treatment of investment			8,758,000			8,758,000
Loss attributed to noncontrolling interest			(330,000)			(330,000)
Gain/(loss) on forgiveness of debt			(6,739,000)			(6,739,000)
(Loss) on fair value adjustment of investments
Gain on deconsolidation of subsidiary
Interest and other expenses			96,000
NET INCOME (LOSS) INCLUDING NONCONTROLLABLE INTEREST			2,117,000
Net (loss) attributable to noncontrolling interest
NET (LOSS) ATTRIBUTABLE TO MANHATTAN SCIENTIFICS, INC.			$ 2,117,000			$ 463,000
BASIC AND DILUTED INCOME (LOSS) PER COMMON SHARE:
Weighted average number of common shares outstanding (Basic)			533,781,064			533,781,064
Basic income (loss) per common share			$ 0.00			$ 0.00
Weighted average number of common shares outstanding (Diluted)			581,036,064			581,036,064
Diluted income (loss) per common share			$ 0.00			$ 0.00
(Adjustments)
Revenue
Operating costs:
Direct cost of revenue			65,000	[1]		127,000	[2]
General and administrative expenses			(57,000)	[3]		(119,000)	[2]
Research and development	[3]		(11,000)	[1]		(11,000)	[2]
Total operating costs and expenses
Loss from operations before other income and expenses
Other income and (expenses):
Gain from change in accounting treatment of investment	[3]		(8,758,000)			(8,758,000)
Loss attributed to noncontrolling interest	[3]		330,000			330,000
Gain/(loss) on forgiveness of debt	[3]		6,739,000			6,739,000
(Loss) on fair value adjustment of investments	[3]		203,000			203,000
Gain on deconsolidation of subsidiary	[3]		7,940,000			7,940,000
Interest and other expenses
NET INCOME (LOSS) INCLUDING NONCONTROLLABLE INTEREST
Net (loss) attributable to noncontrolling interest	[3]		472,000
NET (LOSS) ATTRIBUTABLE TO MANHATTAN SCIENTIFICS, INC.						$ 6,457,000
BASIC AND DILUTED INCOME (LOSS) PER COMMON SHARE:
Weighted average number of common shares outstanding (Basic)
Basic income (loss) per common share
Weighted average number of common shares outstanding (Diluted)
Diluted income (loss) per common share
(Corrected Amount)
Revenue			$ 41,000			$ 83,000
Operating costs:
Direct cost of revenue			65,000			127,000
General and administrative expenses			310,000			1,024,000
Research and development			(669,000)			155,000
Total operating costs and expenses			(294,000)			1,306,000
Loss from operations before other income and expenses			335,000			(1,223,000)
Other income and (expenses):
Gain from change in accounting treatment of investment
Loss attributed to noncontrolling interest
Gain/(loss) on forgiveness of debt
(Loss) on fair value adjustment of investments			203,000			203,000
Gain on deconsolidation of subsidiary			7,940,000			7,940,000
Interest and other expenses			96,000
NET INCOME (LOSS) INCLUDING NONCONTROLLABLE INTEREST			8,574,000
Net (loss) attributable to noncontrolling interest			472,000
NET (LOSS) ATTRIBUTABLE TO MANHATTAN SCIENTIFICS, INC.			$ 9,046,000			$ 6,920,000
BASIC AND DILUTED INCOME (LOSS) PER COMMON SHARE:
Weighted average number of common shares outstanding (Basic)			533,781,064			533,781,064
Basic income (loss) per common share			$ 0.02			$ 0.01
Weighted average number of common shares outstanding (Diluted)			581,036,064			581,036,064
Diluted income (loss) per common share			$ 0.02			$ 0.01

[1] Reclassification from research and development to direct cost of revenue

[2] Reclassification from general and admininstrative and research and development to direct cost of revenue

[3] Deconsolidation of Imagion Biosystems, Inc. and recording investment at fair value